Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
44.29
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock
↗
December 03, 2025
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
↗
December 03, 2025
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Via
The Motley Fool
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?
↗
December 03, 2025
Soleno just turned profitable for the first time—right as a major fund made its move.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
↗
August 08, 2025
Via
Benzinga
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
↗
December 03, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
↗
December 03, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via
The Motley Fool
Topics
Regulatory Compliance
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors
↗
December 03, 2025
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via
The Motley Fool
Topics
Regulatory Compliance
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares
↗
December 03, 2025
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
December 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
November 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
November 06, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
These stocks are moving in today's after hours session
↗
November 03, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Xenon Reports Third Quarter 2025 Financial Results & Business Update
November 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Insights into Xenon Pharmaceuticals's Upcoming Earnings
↗
October 31, 2025
Via
Benzinga
Xenon to Report Q3 2025 Financial Results on November 3, 2025
October 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
October 16, 2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
September 25, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 29, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Second Quarter 2025 Financial Results & Business Update
August 11, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Report Q2 2025 Financial Results on August 11, 2025
August 04, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For August 11, 2025
↗
August 11, 2025
Via
Benzinga
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
↗
July 07, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via
Stocktwits
Xenon Joins the Russell 3000® and Russell 2000® Indexes
June 27, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
June 24, 2025
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.